William Garrett Gray Sells 268,432 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Stock

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO William Garrett Gray sold 268,432 shares of Checkpoint Therapeutics stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $4.01, for a total transaction of $1,076,412.32. Following the transaction, the chief financial officer now directly owns 1,032,754 shares in the company, valued at approximately $4,141,343.54. This represents a 20.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Checkpoint Therapeutics Stock Up 11.3 %

Shares of NASDAQ:CKPT opened at $3.75 on Friday. The firm has a market cap of $183.12 million, a price-to-earnings ratio of -2.04 and a beta of 1.34. Checkpoint Therapeutics, Inc. has a 12 month low of $1.38 and a 12 month high of $4.50. The company’s fifty day simple moving average is $3.59 and its 200 day simple moving average is $2.71.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.08). Research analysts expect that Checkpoint Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CKPT has been the topic of several recent analyst reports. Lake Street Capital lifted their target price on Checkpoint Therapeutics from $4.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, December 16th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Checkpoint Therapeutics in a research report on Monday, December 16th.

Institutional Investors Weigh In On Checkpoint Therapeutics

Several institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC increased its position in shares of Checkpoint Therapeutics by 41.2% in the third quarter. Geode Capital Management LLC now owns 427,651 shares of the company’s stock valued at $958,000 after acquiring an additional 124,787 shares during the last quarter. B. Riley Wealth Advisors Inc. increased its position in Checkpoint Therapeutics by 366.3% during the second quarter. B. Riley Wealth Advisors Inc. now owns 229,200 shares of the company’s stock worth $493,000 after buying an additional 180,050 shares during the last quarter. PVG Asset Management Corp raised its stake in Checkpoint Therapeutics by 9.2% in the third quarter. PVG Asset Management Corp now owns 149,870 shares of the company’s stock valued at $336,000 after buying an additional 12,676 shares during the period. Wealth Enhancement Advisory Services LLC lifted its position in shares of Checkpoint Therapeutics by 160.0% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company’s stock valued at $291,000 after buying an additional 80,000 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Checkpoint Therapeutics by 32.2% during the 3rd quarter. State Street Corp now owns 94,424 shares of the company’s stock worth $212,000 after acquiring an additional 23,000 shares during the period. Institutional investors own 22.00% of the company’s stock.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.